Benadryl recall
This article was originally published in The Tan Sheet
Executive Summary
Pfizer initiates voluntary nationwide recall of Benadryl Allergy & Sinus Fastmelt tablets and Benadryl Children's Allergy/Cold Fastmelt tablets June 1. Products incorrectly state the amount of phenylalanine, contained in aspartame, as 1.2 mg per tablet, Pfizer says; correct amount should read 4.6 mg/tablet. Pfizer stresses the labeling error only affects people with phenylketonuria (PKU), a rare inherited metabolic condition; no adverse events have been reported. Consumers who have purchased a Fastmelt product and do not wish to use it can exchange or return the product for a full refund. Revised labeling should be available in several weeks, firm notes
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning